Company intelligence / Profile preview

Vaxiion Therapeutics

San Diego, California, USAvaxiion.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

Vaxiion’s lead product, VAX014—a first-in-class nonviral tumor-targeted oncolytic immunotherapy—is in early-stage clinical trials. It has shown promise as an intratumoral therapy for patients with advanced solid tumors and has also been evaluated in non-muscle invasive bladder cancer. The company’s proprietary recombinant bacterial minicell platform enables targeted delivery of a variety of therapeutic payloads directly to tumor cells.[1][3][6]

Therapeutic areas: Oncology
Modalities: Bacterial minicell-based delivery systemsOncolytic immunotherapy agentsPotential for small molecules, protein toxins, RNAi, plasmids, peptides, imaging agents[1][6]
Industry: Biotech

Drug pipeline

1 asset

VAX014

Beyond the preview

Go deeper on Vaxiion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaxiion Therapeutics.

Explore the full profile